DC vaccine enhances CAR-T cell antitumor activity by overcoming T cell exhaustion and promoting T cell infiltration in solid tumors
Authors:
- 20 April 2023
- journal article
- research article
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 25 (10) , 2972-2982
Abstract
Objective Great success has been achieved in CAR-T cell immunotherapy in the treatment of hematological tumors. However, it is particularly difficult in solid tumors, because CAR-T is difficult to enter interior and exert long-term stable immune effects. Dendritic cells (DCs) can not only present tumor antigens but also promote the infiltration of T cells. Therefore, CAR-T cells with the help of DC vaccines are a reliable approach to treat solid tumors. Methods To test whether DC vaccine could promote CAR-T cell therapy in solid tumors, DC vaccine was co-cultured with MSLN CAR-T cells. The in vitro effects of DC vaccine on CAR-T were assessed by measuring cell proliferation, cell differentiation, and cytokine secretion. Effects of DC vaccine on CAR-T were evaluated using mice with subcutaneous tumors in vivo. The infiltration of CAR-T was analyzed using immunofluorescence. The persistence of CAR-T in mouse blood was analyzed using real-time quantitative PCR. Results The results showed that DC vaccine significantly enhanced the proliferation potential of MSLN CAR-T cells in vitro. DC vaccines not only promoted the infiltration of CAR-T cells, but also significantly improved the persistence of CAR-T in solid tumors in vivo. Conclusion In conclusion, this study has demonstrated that DC vaccine can promote CAR-T therapy in solid tumors, which provides the possibility of widespread clinical application of CAR-T cells in the future.Keywords
Funding Information
- National Natural Science Foundation of China (81872284)
This publication has 41 references indexed in Scilit:
- CAR T Cell Therapy for Solid TumorsAnnual Review of Medicine, 2017
- CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patientsJournal of Clinical Investigation, 2016
- Dendritic Cell–Based Immunotherapy: State of the Art and BeyondClinical Cancer Research, 2016
- Different Subsets of T Cells, Memory, Effector Functions, and CAR-T ImmunotherapyCancers, 2016
- Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivoLeukemia, 2015
- Current Status and Future Perspectives of Dendritic Cell–Based Cancer ImmunotherapyScandinavian Journal of Immunology, 2013
- Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trialCytotherapy, 2009
- Dendritic cell microvilli: a novel membrane structure associated with the multifocal synapse and T-cell clusteringBlood, 2008
- Dendritic Cell-Based ImmunotherapyInternational Reviews of Immunology, 2006
- Manipulating dendritic cell biology for the active immunotherapy of cancerBlood, 2004